The objective response to durvalumab (PD-L1 mAb) in treating urothelial carcinoma with high expression of PD-L1 was only 26.3%, while for urothelial carcinoma with low or no PD-L1 expression, the objective response was merely 4.1% 7. The gene discussed is CD274; the disease is urothelial carcinoma.